Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: PF-04958242
Drug: Placebo

First Posted Date: 2015-01-07

Last Posted Date: 2021-10-25

Lead Sponsor: Biogen

Target Recruit Count: 39

Registration Number: NCT02332798

Locations: 🇺🇸
Collaborative Neuroscience Network, LLC., Long Beach, California, United States

Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)

Terminated

Conditions: Multiple Sclerosis, Relapsing-Remitting
Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: dimethyl fumarate

First Posted Date: 2014-12-23

Last Posted Date: 2016-04-08

Lead Sponsor: Biogen

Target Recruit Count: 24

Registration Number: NCT02323269

Locations: 🇨🇦
Research Site, Montreal, Quebec, Canada

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

Phase 1

Completed

Conditions: Tauopathies

Interventions: Drug: BMS-986168
Drug: BMS-986168 Placebo

First Posted Date: 2014-11-19

Last Posted Date: 2017-11-06

Lead Sponsor: Biogen

Target Recruit Count: 65

Registration Number: NCT02294851

Locations: 🇺🇸
WCCT Global, LLC, Cypress, California, United States
🇺🇸
Covance Clinical Research Unit Inc., Dallas, Texas, United States

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

Phase 3

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Procedure: Sham procedure
Drug: Nusinersen

First Posted Date: 2014-11-17

Last Posted Date: 2021-02-17

Lead Sponsor: Biogen

Target Recruit Count: 126

Registration Number: NCT02292537

Locations: 🇺🇸
UCLA Clinical and Translational Research Center, Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 21 locations

Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery

Completed

Conditions: Healthy

First Posted Date: 2014-11-05

Last Posted Date: 2015-10-05

Lead Sponsor: Biogen

Target Recruit Count: 467

Registration Number: NCT02283918

Locations: 🇺🇸
Research Site, Akron, Ohio, United States
🇮🇹
Research site, Roma, Italy

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Phase 3

Active, not recruiting

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: Interferon β-1a
Drug: dimethyl fumarate

First Posted Date: 2014-11-05

Last Posted Date: 2024-07-16

Lead Sponsor: Biogen

Target Recruit Count: 156

Registration Number: NCT02283853

Locations: 🇧🇬
MHATNP 'Sv.Naum', EAD, Sofia, Bulgaria
🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel
🇫🇷
Hopital Roger Salengro - CHU Lille, Lille Cedex, Nord, France

and more 59 locations